FoRx Therapeutics raises Eur 10M seed-financing round: the advisor

FoRx Therapeutics, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round led by M Ventures (venture capital arm of Merck), Novartis Venture Fund and Omega Funds. Pfizer Ventures, the venture capital arm of Pfizer and Life Sciences Partners also joined the seed-financing. In this context, FoRx is developing a new generation of drugs against a unique target class for the treatment of cancer.

The team

VISCHER advises FoRx Therapeutics on all Swiss legal issues in this transaction. The team includes partner Christian Wyss (life sciences – pictured), associates Dania Salvisberg-Schneider, Luzius Zumstein (both corporate and m&a), Fiona Gao (life sciences), Beatrice Leistner (tax), and Gian Geel (employment).
FoRx Therapeutics raises Eur 10M seed-financing round: the advisor


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram